Document:

Letter Agreement dated February 25, 2008 between Sigma-Aldrich Corporation

 Exhibit 10.2 
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a
“[***]” in place of the redacted language. The redacted information has been filed separately with the Commission. 
  

			
	

	  	Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000
(Tel)
510-236-8951(Fax)
	 Expressing Life
	  	

 February 25, 2008 
 David A. Smoller, Ph.D. 
 President 
 Biotechnology
Business Unit 
 Sigma-Aldrich Co. 
 3050 Spruce Street,

 St. Louis, MO 63103 
  

	Re:	License Agreement—Genentech Custom Project 

 Dear Dave:

 In connection with the License Agreement dated July 10, 2007 (the “Agreement”), by and between Sangamo BioSciences, Inc.
(“Sangamo”) and Sigma-Aldrich Co. (“Sigma”), as amended, Sigma and Sangamo hereby agree as set forth below. 
 1. Pursuant to a
certain Research and License Agreement, effective as of April 27, 2007 (the “Existing Sangamo/Genentech Agreement”), Sangamo is obligated to perform certain custom project services for Genentech, Inc. (“Genentech”) with
respect to [***] named in such Existing Sangamo/Genentech Agreement. This confirms that as between Sigma and Sangamo, Sangamo’s rights and obligations under the Existing Sangamo/Genentech Agreement are as set out in Section 6.1(a) of the
Agreement and in Sections 6, 7 and 8 of this letter agreement. 
 2. Genentech desires that certain additional custom services projects be performed
with respect to additional targets to be selected by Genentech (“Additional Services”). 
 3. Under Sections 6.1(b) and (c) of the
Agreement, Sigma (and not Sangamo) has the right to enter into the contractual relationship with Genentech with respect to such Additional Services. Notwithstanding the foregoing, in light of the relationship between Genentech and Sangamo under the
Existing Sangamo/Genentech Agreement and for the sake of expediency, Sigma and Sangamo agree that Sangamo (and not Sigma) will enter into an agreement with Genentech to perform the Additional Services (the “New Sangamo/Genentech
Agreement”), as enabled by and in accordance with the provisions of this letter agreement. An unexecuted copy 

  

 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
of the final version of the New Sangamo/Genentech Agreement is attached to this letter agreement as Exhibit A. The Existing Sangamo/Genentech Agreement and
the New Sangamo/Genentech Agreement are referred to collectively as the “Sangamo/Genentech Agreements.” 
 4. Sangamo and Sigma agree that
[***] 
 5. The foregoing is not intended to limit Sangamo’s obligation, other than to the extent provided in any Assumption Agreement(s), under
the New Sangamo/Genentech Agreement to perform the Additional Services or Sangamo’s obligation under the Agreement to perform certain activities with respect to custom services projects in the Field generally, including without limitation the
Manufacture and supply of Active Supplied ZFNs and/or Modified Cell Lines. 
 6. Notwithstanding the exclusive nature of any licenses granted to Sigma
in the Agreement or any other terms of the Agreement, Sigma agrees that Sangamo is permitted to grant the rights and licenses to Genentech that are specified in the New Sangamo/Genentech Agreement (including without limitation the licenses set forth
in Sections 5.1(a) and 5.1(d) therein) and otherwise to perform Sangamo’s obligations that are set forth in the New Sangamo/Genentech Agreement, and the grant of such licenses and performance of such obligations do not violate the terms of the
Agreement. 
 7. Sigma confirms that Sangamo’s grant of an exclusive license to Sigma in the Agreement was made expressly subject to the rights
granted to Genentech in the Existing Sangamo/Genentech Agreement, and, as a result, Sangamo is permitted to perform Sangamo’s obligations that are set forth in the Existing Sangamo/Genentech Agreement and the performance of such obligations
does not violate the terms of the Agreement. 
 8. Without limiting the provisions of this letter agreement: 
 (a) Subject to the other terms of this Section 8(a), Sigma hereby grants to Sangamo a non-exclusive, worldwide, sublicensable license, under
the Sigma IP Rights (as defined below), (i) to make, use and import ZFN Reagents (as defined in the Sangamo/Genentech Agreements) (and any associated expression plasmids provided by Sangamo to Genentech under the Sangamo/Genentech Agreements)
solely for the purpose of altering the genomic DNA of any of the Designated Genes (as defined in the Sangamo/Genentech Agreements) in a cell line to create ZFN Modified Cell Lines (as defined in the Sangamo/Genentech Agreements); (ii) to alter
the genomic DNA of any of the Designated Genes in a cell line to create Modified Cell Lines (as defined in the Sangamo/Genentech Agreements); and (iii) to make, use and import Modified Cell Lines created under clauses (i) and
(ii) solely for the purpose of making Licensed Products (as defined in the Sangamo/Genentech Agreements). The license set forth in (i)-(iii) of the previous sentence shall terminate with respect to a particular Designated Gene immediately upon
the termination of the license granted by Sangamo to Genentech with respect to such Designated Gene, as set forth in the applicable Sangamo/Genentech Agreement. For the purpose of this letter agreement, “Sigma IP Rights” means Sigma’s
intellectual property rights in (A) Know-How (as defined in the Sangamo/Genentech Agreements) that is Controlled by (as defined in the Sangamo/Genentech Agreements mutatis mutandis) Sigma, existing as of the effective 

  

 2. 
 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
date of the Agreement or thereafter, to the extent necessary or reasonably useful to make or use (including for validation purposes) ZFN Reagents and/or ZFN
Modified Cell Lines or (B) Patents (as defined in the Sangamo/Genentech Agreements) that are Controlled by Sigma, existing as of the effective date of the Agreement or thereafter, having one or more claims that encompass ZFN Reagents and/or ZFN
Modified Cell Lines and/or the making and/or use of ZFN Reagents and/or ZFN Modified Cell Lines. To the extent that the foregoing license includes rights that are expressly licensed to Sangamo under the Agreement, the foregoing license is intended
merely to confirm such rights and shall not be construed as limiting any licenses granted to Sangamo under the Agreement. To the extent that the foregoing license includes rights that are not expressly licensed to Sangamo under the Agreement,
Sangamo shall have the right to grant sublicenses under such rights solely to Genentech, and Sangamo (but, for clarity, not Genentech) agrees to practice such rights solely for the purpose of performing its obligations under the Sangamo/Genentech
Agreements. 
 (b) [***] 
 (c) [***] 
 (d) [***] 
 (e) To the extent that Genentech receives, pursuant to each of the Sangamo/Genentech Agreements, a sublicense under any license granted by Sigma to Sangamo under the Agreement or under this letter agreement,
any such sublicense may be further sublicensed by Genentech to multiple tiers of sublicensees, and such sublicense (including any further sublicenses thereunder) shall survive the termination of the Agreement, this letter agreement, or
Sangamo’s license rights under the foregoing agreements, provided that Genentech is not then in default under the applicable Sangamo/Genentech Agreement. 
 9. Sigma and Sangamo agree: 
 (a) Sangamo shall pay to Sigma [***] of each of the following payments received by
Sangamo from Genentech under the New Sangamo/Genentech Agreement: 
 (i) [***] 
 (ii) [***] 
 (iii) [***] 
 (iv) [***] 
 (b) Payments by Sangamo under Section 9(a) of this letter agreement shall be made within [***] of Sangamo’s receipt of the relevant
payment from Genentech. Sections 7.11-7.15 of the Agreement shall apply to all payments made under this letter agreement. 
 (c) The
portion of the Genentech payments described in Section 9(a) of this letter agreement that are retained by Sangamo (i.e., [***] of such payments) shall be deemed to fully satisfy Sigma’s obligations under Section 7.7 of the Agreement.

  

 3. 
 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (d) Solely for the purpose of Section 7.5 of the Agreement, the portion of the Genentech
payments described in Section 9(a) of this letter agreement that is retained by Sangamo (i.e., [***] of such payments) shall be deemed to be royalty payments received by Sangamo and shall be deemed to be in respect of sales occurring in the
calendar quarter in which Sangamo received such payments from Genentech. For clarity, such Genentech payments described in Section 9(a) of this letter agreement shall not constitute Sublicensing Revenue for purposes of the Agreement.

 (e) Sangamo shall use Diligent Efforts (as defined in the Agreement) to promptly bill and collect amounts due Sangamo pursuant to
Sections 3.2, 3.3, 3.4 and 3.5 of the New Sangamo/Genentech Agreement. 
 (f) Any Custom Product Deliverables provided by Sangamo to
Genentech under the New Sangamo/Genentech Agreement shall count towards the [***], as set forth in Section 6.2(b) of the Agreement. Sigma shall owe the payment(s) specified in Section 6.2(b) of the Agreement if the Custom Product
Deliverables provided by Sangamo to Genentech under the New Sangamo/Genentech Agreement causes Sangamo to exceed such maximum. 
 (g)
Notwithstanding anything to the contrary herein, Sangamo shall retain one hundred percent (100%) of all payments made to Sangamo under the Existing Sangamo/Genentech Agreement. 
 10. Sangamo and Sigma further agree: 
 (a) For the avoidance of doubt, the Subject Matter (as
defined in Section 4.3(a) of the New Sangamo/Genentech Agreement) shall be deemed to be a “Sangamo Improvement” pursuant to the Agreement, and any resulting patent or patent application that claims such Subject Matter shall be deemed
to be a “Sangamo Patent” and included within “Sangamo Technology” pursuant to the Agreement. 
 (b) For the
avoidance of doubt, the obligation of Sangamo to indemnify, defend and hold Sigma harmless pursuant to Section 12.1(d) of the Agreement includes obligations owed by Sangamo to Genentech pursuant to the Sangamo/Genentech Agreements. 

(c) Sangamo further agrees that, solely for the purposes of evaluating whether Sangamo is in breach of its obligations under the Agreement and
determining Sangamo’s liability therefor, Sangamo’s obligation to perform the Research (as defined in the New Sangamo/Genentech Agreement) for Genentech shall be deemed to be a “collaborative service reasonably necessary for the
performance by Sigma of the Custom Projects,” as such phrase is used in Section 6.2 of the Agreement. 
 (d) Notwithstanding
any provision of the Agreement to the contrary, Sangamo (and not Sigma) shall be responsible for paying all fees, milestones, royalties and other compensation owed to Third Parties pursuant to Third Party Licenses identified in Exhibit B of the
Agreement on account of the grant to Genentech of the licenses set forth in the New Sangamo/Genentech Agreement, or the (ii) the generation, development and/or commercialization of Licensed Products (as defined in the New Sangamo/Genentech
Agreement) by Genentech. 
  

 4. 
 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (e) Sangamo will promptly provide to Sigma a copy of all notices received by Sangamo from
Genentech pursuant to the New Sangamo/Genentech Agreement with respect to the Additional Services to the extent such obligations involve the performance of a custom service project in the Field for Genentech. 
 (f) Prior to providing any notice to Genentech under Section 2.1(b) of the New Sangamo/Genentech Agreement with respect to the Additional
Services, to the extent such obligations involve the performance of a custom service project in the Field for Genentech, Sangamo will first review such notice with Sigma and consider any comments of Sigma in good faith. 
 11. As between Sangamo and Sigma, the following information is the Confidential Information of Sangamo under the Agreement (whether or not so marked) and may only
be used by Sigma for the benefit of Genentech: (a) the New Sangamo/Genentech Agreement, including the version attached to this letter agreement as Exhibit A and any earlier drafts provided by Sangamo to Sigma; (b) the Existing
Sangamo/Genentech Agreement, a copy of which was provided by Sangamo to Sigma; (c) any notices provided by Sangamo to Sigma under Sections 10(e) or 10(f) of this letter agreement; and (d) any other Confidential Information (as defined
in the Sangamo/Genentech Agreements) of Genentech provided by Sangamo to Sigma in connection with either of the Sangamo/Genentech Agreements). 
 12.
The Agreement is hereby amended to the extent necessary to implement the provisions of this letter agreement. Sangamo and Sigma agree that Genentech is an express third party beneficiary of (with the right to enforce) such provisions (other than the
provisions in Sections 9 and 10 of this letter agreement), whether or not Sangamo shall have first undertaken the enforcement thereof. 
 Any
capitalized term used in this letter agreement that is not defined herein shall have the meaning given to such term in the Agreement. 
 Please confirm
Sigma’s acknowledgment and agreement by signing below. 
 Sincerely, 

	
	
	/s/ Edward Lanphier
	Edward Lanphier
	President and Chief Executive Officer

  

 5. 

 Acknowledged and Agreed: 
 Sigma-Aldrich Co. 
  

			
		
	By:	 	/s/ David A. Smoller
		 	David A. Smoller, Ph.D.
		 	President, Biotechnology Business Unit

  

 6. 

 Exhibit A 
 New Sangamo/Genentech Agreement 
 (ATTACHED) 
  

 7.Third Amendment to the Second Amended And Restated Credit Agreement

 EXHIBIT 4.1 
 THIRD AMENDMENT TO 
 SECOND AMENDED AND RESTATED CREDIT AGREEMENT 
 THIS THIRD AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of April 28, 2008, is
entered into among AMN HEALTHCARE, INC., a Nevada corporation (the “Borrower”), AMN HEALTHCARE SERVICES, INC., a Delaware corporation (the “Parent”), the Subsidiary Guarantors from time to time parties
thereto, the lenders identified on the signature pages hereto (the “Lenders”) and BANK OF AMERICA, N.A., as Administrative Agent. 
 W I T N E S S E T H 
 WHEREAS, the Borrower, the Parent, the Subsidiary Guarantors, the
Lenders party thereto, and the Administrative Agent entered into that certain Second Amended and Restated Credit Agreement dated as of November 2, 2005, as amended by that certain First Amendment to Second Amended and Restated Credit Agreement
dated as of May 1, 2006 and as amended by that certain Second Amendment to Second Amended and Restated Credit Agreement dated as of July 6, 2007 (the “Existing Credit Agreement”); 
 WHEREAS, the Borrower has requested that the Lenders amend certain provisions of the Existing Credit Agreement; 
 WHEREAS, the Lenders have agreed to amend the Existing Credit Agreement in accordance with such request and as provided herein; and 
 NOW, THEREFORE, in consideration of the agreements hereinafter set forth, and for other good and valuable consideration, the receipt and adequacy
of which are hereby acknowledged, the parties hereto agree as follows: 
 PART 1 
 DEFINITIONS 
 SUBPART 1.1
Certain Definitions. Unless otherwise defined herein or the context otherwise requires, the following terms used in this Amendment, including its preamble and recitals, have the following meanings: 
 “Amended Credit Agreement” means the Existing Credit Agreement as amended hereby. 
 “Third Amendment” has the meaning set forth in Subpart 3.1. 
 SUBPART 1.2 Other Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Amendment, including
its preamble and recitals, have the meanings provided in the Existing Credit Agreement. 
  

 PART 2 
 AMENDMENTS TO EXISTING CREDIT AGREEMENT 
 Effective on (and subject to the occurrence of) the Third
Amendment Effective Date, the Existing Credit Agreement is hereby amended in accordance with this Part II. 
 SUBPART 2.1
Amendment to Section 1.1. Subsection (viii) of the definition of “Permitted Lien” found in Section 1.1 is hereby amended as follows: 
 (viii) Liens securing Indebtedness permitted by Sections 8.1(g) and 8.1(k); 
 SUBPART 2.2 Amendment to Section 8.1. Section 8.1 is hereby amended by (i) deleting the “and” before existing
clause (k), (ii) replacing “(k)” in existing clause (k) with “(l)” and (iii) adding the following as new clause (k): 
 (k) other secured Indebtedness of the Borrower or any of its Subsidiaries in an aggregate principal amount not to exceed $15,000,000 at any one time outstanding; provided that any such secured Indebtedness shall be
subject to an intercreditor agreement on terms and conditions reasonably acceptable to the Administrative Agent; and 
 SUBPART 2.3
Amendment to Section 8.7. Subsection (k) of Section 8.7 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 (k) the repurchase, redemption or other acquisition or retirement for value of any Capital Stock of the Parent or any option to acquire
Capital Stock of the Parent in an aggregate cash amount not to exceed $50,000,000 in the aggregate; provided that (x) no Default or Event of Default exists either before or after giving effect to such Restricted Payment and (y) such
repurchase, redemption or other acquisition or retirement occurs on or before March 31, 2009, and 
 SUBPART 2.4 Amendment to
Section 8.14. Section 8.14 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 8.14 Capital Expenditures. 
 The Credit Parties will not permit Consolidated Capital Expenditures for
any fiscal year to exceed $15,000,000 plus the unused amount available for Consolidated Capital Expenditures under this Section 8.14 for the immediately preceding fiscal year (excluding any carry forward available from any prior fiscal
year). 
 PART 3 
 CONDITIONS TO EFFECTIVENESS 
 SUBPART 3.1 Third Amendment Effective Date. This Amendment shall be and become
effective as of the date hereof when all of the conditions set forth in this Part 3 shall have been satisfied, and thereafter this Amendment shall be known, and may be referred to, as the “Third Amendment”. 
  

 2 

 SUBPART 3.2 Execution of Counterparts of Amendment. The Administrative Agent shall have
received counterparts of this Amendment, which collectively shall have been duly executed on behalf of each of the Borrower, the Parent, the Subsidiary Guarantors, the Requisite Lenders, Lenders (other than Defaulting Lenders) holding in the
aggregate at least a majority of the Revolving Commitments and the Administrative Agent. 
 SUBPART 3.3 Fees and Expenses. The
Administrative Agent shall have received from the Borrower (i) the aggregate amount of fees and expenses payable to the Administrative Agent and Banc of America Securities LLC in connection with the consummation of the transactions contemplated
hereby, (ii) for the account of each Lender approving this Amendment by 12:00 p.m. Eastern Standard Time on April 25, 2008, an amendment fee equal to 25 basis points on such Lender’s Commitment and (iii) all reasonable and
documented out-of-pocket costs and expenses of the Administrative Agent in connection with the preparation, execution and delivery of this Amendment, including without limitation the reasonable fees and expenses of Moore & Van Allen PLLC,
special counsel to the Administrative Agent. 
 PART 4 
 MISCELLANEOUS 
 SUBPART 4.1 Representations and Warranties. The Borrower hereby
represents and warrants to the Administrative Agent and the Lenders that, after giving effect to this Amendment, (a) no Default or Event of Default exists under the Existing Credit Agreement, after giving effect to this Amendment and
(b) the representations and warranties set forth in Section 6 of the Existing Credit Agreement are, subject to the limitations set forth therein, true and correct in all material respects as of the date hereof (except for those which
expressly relate to an earlier date, in which case, they are true and correct in all material respects as of such earlier date). 
 SUBPART 4.2 Cross-References. References in this Amendment to any Part or Subpart are, unless otherwise specified, to such Part or Subpart of this Amendment. 
 SUBPART 4.3 Instrument Pursuant to Existing Credit Agreement. This Amendment is executed pursuant to the Existing Credit Agreement and
shall (unless otherwise expressly indicated therein) be construed, administered and applied in accordance with the terms and provisions of the Existing Credit Agreement. 
 SUBPART 4.4 References in Other Credit Documents. At such time as this Amendment shall become effective pursuant to the terms of Subpart 3.1, all references to the “Credit Agreement”
shall be deemed to refer to the Existing Credit Agreement as amended by this Amendment. 
 SUBPART 4.5 Counterparts. This
Amendment may be executed by the parties hereto in several counterparts, each of which shall be deemed to be an original and all of which shall constitute together but one and the same agreement. Delivery of executed counterparts of the Amendment by
facsimile or electronic mail shall be effective as an original and shall constitute a representation that an original shall be delivered. 
  

 3 

 SUBPART 4.6 Governing Law. THIS AMENDMENT SHALL BE DEEMED TO BE A CONTRACT MADE UNDER AND
GOVERNED BY THE LAWS OF THE STATE OF NEW YORK. 
 SUBPART 4.7 Acknowledgment. The Guarantors acknowledge and consent to all of
the terms and conditions of this Amendment and agree that this Amendment does not operate to reduce or discharge the Guarantors’ obligations under the Existing Credit Agreement as amended by this Amendment or the other Credit Documents. The
Guarantors further acknowledge and agree that the Guarantors have no claims, counterclaims, offsets, or defenses to the Credit Documents and the performance of the Guarantors’ obligations thereunder or if the Guarantors did have any such
claims, counterclaims, offsets or defenses to the Credit Documents or any transaction related to the Credit Documents, the same are hereby waived, relinquished and released in consideration of the Lenders’ execution and delivery of this
Amendment. Each Guarantor also hereby confirms and agrees that notwithstanding the effectiveness of this Amendment, the Collateral Documents to which each of the undersigned is a party and all of the Collateral described therein do, and shall
continue to, secure the payment of all of the Credit Party Obligations. 
 SUBPART 4.8 Binding Effect. This Amendment, the
Existing Credit Agreement as amended by this Amendment and the other Credit Documents embody the entire agreement between the parties and supersede all prior agreements and understandings, if any, relating to the subject matter hereof. These Credit
Documents represent the final agreement between the parties and may not be contradicted by evidence of prior, contemporaneous or subsequent oral agreements of the parties. Except as expressly modified and amended in this Amendment, all the terms,
provisions and conditions of the Credit Documents shall remain unchanged and shall continue in full force and effect. 
 SUBPART 4.9
Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. 
 SUBPART 4.10 General. Except as amended hereby, the Existing Credit Agreement and all other credit documents shall continue in full force and effect. 
 SUBPART 4.11 Severability. If any provision of this Amendment is determined to be illegal, invalid or unenforceable, such provision shall
be fully severable and the remaining provisions shall remain in full force and effect and shall be construed without giving effect to the illegal, invalid or unenforceable provisions. 
 [Remainder of Page Intentionally Left Blank] 
  

 4 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment to the Credit Agreement as of
the date first above written. 
  

							
	BORROWER:	 		 	AMN HEALTHCARE, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
	PARENT:	 		 	AMN HEALTHCARE SERVICES, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
	 SUBSIDIARY
 GUARANTORS:
	 		 	AMN SERVICES, INC. (formerly known as Worldview Healthcare, Inc.)
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	O’GRADY-PEYTON INTERNATIONAL (USA), INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	INTERNATIONAL HEALTHCARE RECRUITERS, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer

  

 5 

							
		 		 	AMN STAFFING SERVICES, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	THE MHA GROUP, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	MERRITT, HAWKINS & ASSOCIATES
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	MED TRAVELERS, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	RN DEMAND, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	STAFF CARE, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer

  

 6 

							
		 		 	MHA ALLIED CONSULTING, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	MED TRAVELERS, LLC
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	LIFEWORK, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	PHARMACY CHOICE, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	RX PRO HEALTH, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer
			
		 		 	PLATINUM SELECT HEALTHCARE STAFFING, INC.
				
		 		 	By:	 	 /s/ David C. Dreyer

		 		 	Name:	 	David C. Dreyer
		 		 	Title:	 	Chief Financial Officer

 [Signatures Continued] 
  

 7 

							
	ADMINISTRATIVE AGENT:	 		 	 BANK OF AMERICA, N. A.,
 in its
capacity as Administrative Agent

				
		 		 	By:	 	 /s/ Alysa Trakas

		 		 	Name:	 	Alysa Trakas
		 		 	Title:	 	Vice President
			
	LENDERS:	 		 	 BANK OF AMERICA, N. A.,
 in its
capacity as Lender, Issuing Lender and Swingline Lender

				
		 		 	By:	 	 /s/ Alysa Trakas

		 		 	Name:	 	Alysa Trakas
		 		 	Title:	 	Vice President

 [Signatures Continued] 
  

 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]